← Back to Search

Mitochondrial Antioxidant

MitoQ for Cardiovascular Disease (MOVHS Trial)

N/A
Recruiting
Led By Austin T Robinson, PhD
Research Sponsored by Auburn University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up changes from before and after 8 week supplementation and placebo
Awards & highlights

Summary

This trial will assess if a mitochondrial antioxidant (MitoQ) can reduce CVD risk among Black Americans, who are disproportionately affected by CVD. Researchers will measure blood pressure, vascular function, and biomarkers of kidney function before & after 8 weeks of MitoQ/placebo.

Who is the study for?
This trial is for middle-aged and older adults (45-75 years old) who are generally healthy but at risk of cardiovascular disease, particularly Black Americans. Participants must not have medical conditions that prevent exercise, giving blood, or allergies to MitoQ ingredients. They should have a BMI under 40 Kg/m2 and blood pressure below 150/90 mmHg without a history of serious diseases like cancer, diabetes, or heart issues.Check my eligibility
What is being tested?
The study tests if the antioxidant MitoQ can reduce oxidative stress and improve vascular health over an 8-week period in individuals at risk for cardiovascular disease. It involves daily consumption of MitoQ compared to a placebo while also considering social factors and health behaviors.See study design
What are the potential side effects?
While specific side effects aren't listed here, participants will be monitored for any adverse reactions due to MitoQ which could include typical supplement-related side effects such as digestive discomfort or allergic reactions.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline (pre-intervention)
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline (pre-intervention) for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Changes in blood biomarkers of nitric oxide bioavailability
Changes in blood pressure reactivity
Changes in circulating reactive oxygen species
+3 more
Secondary outcome measures
Habitual dietary intake
Mental health - depression
Objective sleep duration
+11 more

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: MitoQExperimental Treatment1 Intervention
8-week MitoQ supplementation (20 mg daily capsule).
Group II: PlaceboPlacebo Group1 Intervention
8-week placebo matched in appearance to MitoQ supplementation (20 mg daily capsule).
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
MitoQ
2006
Completed Phase 2
~230

Find a Location

Who is running the clinical trial?

Auburn UniversityLead Sponsor
74 Previous Clinical Trials
14,403 Total Patients Enrolled
Austin T Robinson, PhDPrincipal InvestigatorKinesiology Building
3 Previous Clinical Trials
190 Total Patients Enrolled

Media Library

MitoQ (Mitochondrial Antioxidant) Clinical Trial Eligibility Overview. Trial Name: NCT05561556 — N/A
Cardiovascular Disease Research Study Groups: Placebo, MitoQ
Cardiovascular Disease Clinical Trial 2023: MitoQ Highlights & Side Effects. Trial Name: NCT05561556 — N/A
MitoQ (Mitochondrial Antioxidant) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05561556 — N/A
~34 spots leftby Aug 2026
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top